<p>Erasca, Inc.（纳斯达克代码：ERAS - 获取免费报告）在周三的交易中上涨了 7.7%，此前 HC Wainwright 将该股票的目标价从 6.00 美元上调至 11.00 美元。HC Wainwright 目前对该股票给予买入评级。Erasca 的股价最高达到 8.31 美元，最后交易价格为 8.0890 美元。在交易中，共成交 1,859,162 股，较平均交易量 10,915,956 股下降了 83%。该股票此前收盘价为 7.51 美元。</p>
<p>其他一些券商也对 ERAS 发布了报告。摩根士丹利在 1 月 8 日的研究报告中将 Erasca 的目标价设定为 4.00 美元。瑞穗证券在 12 月 9 日的研究报告中将 Erasca 的目标价从 4.00 美元上调至 5.00 美元，并给予该股票 “跑赢大盘” 的评级。Stifel Nicolaus 在周一的报告中将 Erasca 的目标价设定为 10.00 美元。Weiss Ratings 在 10 月 8 日的报告中重申了对 Erasca 的 “卖出（d-）” 评级。最后，Piper Sandler 在 1 月 7 日的研究报告中开始覆盖 Erasca，给予 “增持” 评级和 5.00 美元的目标价。七位分析师对该股票给予买入评级，一位给予持有评级，两位给予卖出评级。根据 MarketBeat 的数据，Erasca 目前的平均评级为 “适度买入”，平均目标价为 5.44 美元。</p>
<p><strong>获取我们对 Erasca 的最新股票分析</strong></p>
<h2>Erasca 的内部活动</h2>
<p>在 Erasca 的其他新闻中，首席法律顾问 Ebun Garner 在 1 月 7 日的交易中出售了 120,000 股公司的股票。该股票以平均价格 5.59 美元出售，总价值为 670,800.00 美元。交易后，首席法律顾问持有 25,076 股公司的股票，价值约为 140,174.84 美元。此次交易使其持股减少了 82.72%。该交易已在提交给证券交易委员会的文件中披露，可以通过此超链接访问。公司内部人士持有公司股票的 14.40%。</p>
<h2>机构投资者对 Erasca 的看法</h2>
<p>最近，一些机构投资者和对冲基金对该股票的持仓进行了调整。SG Americas Securities LLC 在第四季度将其在 Erasca 的持股增加了 233.3%。SG Americas Securities LLC 目前持有 48,677 股公司股票，价值 181,000 美元，此前在该期间购买了 34,072 股。CIBC Bancorp USA Inc.在第三季度获得了 Erasca 的新股份，价值约为 40,000 美元。Vivo Capital LLC 在第三季度将其在 Erasca 的持股增加了 37.2%。Vivo Capital LLC 目前持有 9,273,428 股公司股票，价值 20,216,000 美元，此前在该期间购买了 2,516,672 股。Paradigm Biocapital Advisors LP 在第三季度将其在 Erasca 的股份增加了 13.9%。Paradigm Biocapital Advisors LP 目前持有 13,560,017 股公司股票，价值 29,561,000 美元，此前在上个季度购买了 1,652,835 股。最后，Creative Planning 在第三季度将其在 Erasca 的股份增加了 43.4%。Creative Planning 目前持有 350,314 股公司股票，价值 764,000 美元，此前在上个季度购买了 105,982 股。机构投资者持有公司 67.78% 的股票。</p>
<h2>Erasca 的价格表现</h2>
<p>该股票的市值为 23.1 亿美元，市盈率为-17.98，贝塔值为 1.15。该公司有 50 日简单移动平均线为 3.46 美元，200 日简单移动平均线为 2.38 美元。</p>
<p>Erasca（纳斯达克代码：ERAS - 获取免费报告）最近在 11 月 12 日发布了其财报。公司报告每股收益为（0.11 美元），符合分析师的共识预期（0.11 美元）。卖方分析师预计 Erasca, Inc.在当前财年将发布每股收益-0.73 美元。</p>
<h2>Erasca 公司简介</h2>
<p>（获取免费报告）</p>
<p>Erasca, Inc 是一家临床阶段的生物制药公司，致力于为癌症患者发现和开发精准医疗。该公司专注于小分子治疗药物，针对肿瘤生长和存活中涉及的关键信号通路，主要强调 MAPK 通路的抑制剂。Erasca 的方案旨在提供口服的靶向治疗，解决肿瘤基因驱动和免疫肿瘤学的适应症，旨在改善满足医疗需求的患者的治疗效果。</p>
<p>Erasca 的研发管线包括多个开发候选药物，包括旨在干扰癌细胞信号传导关键节点的小分子抑制剂。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票比 Erasca 更好</li>
<li>崩盘已经开始（大多数人只是不知道而已）</li>
<li>特朗普计划利用公共法 63-43：现在准备好</li>
<li>股票即将迎来 “不祥之日”……</li>
<li>如果你在美国银行账户中存放现金……请立即阅读</li>
<li>将这些代码输入你的普通经纪账户</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Erasca 吗？</h2>
<p>在考虑 Erasca 之前，你需要听听这个。</p>
<p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每日推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐现在购买，以便在更广泛的市场意识到之前……而 Erasca 并不在名单上。</p>
<p>虽然 Erasca 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

ERAS

<p>Erasca（纳斯达克代码：ERAS）股价上涨 7.7%，在 HC Wainwright 将其目标价从 6.00 美元上调至 11.00 美元，并维持买入评级后，该股交易价格为 8.0890 美元，成交量较平均水平下降 83%。其他分析师的目标价各不相同，其中七位分析师给予买入评级。Erasca 是一家临床阶段的生物制药公司，专注于精准癌症疗法。该公司的市值为 23.1 亿美元，市盈率为-17.98。公司报告每股收益为（0.11 美元），与分析师预期一致</p>

<p>Erasca, Inc. (NASDAQ:ERAS - Get Free Report) traded up 7.7% during trading on Wednesday after HC Wainwright raised their price target on the stock from $6.00 to $11.00. HC Wainwright currently has a buy rating on the stock. Erasca traded as high as $8.31 and last traded at $8.0890. 1,859,162 shares were traded during trading, a decline of 83% from the average session volume of 10,915,956 shares. The stock had previously closed at $7.51.</p>
<div class="lb-trans"><p>Erasca, Inc.（纳斯达克代码：ERAS - 获取免费报告）在周三的交易中上涨了 7.7%，此前 HC Wainwright 将该股票的目标价从 6.00 美元上调至 11.00 美元。HC Wainwright 目前对该股票给予买入评级。Erasca 的股价最高达到 8.31 美元，最后交易价格为 8.0890 美元。在交易中，共成交 1,859,162 股，较平均交易量 10,915,956 股下降了 83%。该股票此前收盘价为 7.51 美元。</p>
</div><p>A number of other brokerages have also issued reports on ERAS. Morgan Stanley set a $4.00 target price on Erasca in a research report on Thursday, January 8th. Mizuho upped their price target on shares of Erasca from $4.00 to $5.00 and gave the stock an &#34;outperform&#34; rating in a research report on Tuesday, December 9th. Stifel Nicolaus set a $10.00 price objective on shares of Erasca in a report on Monday. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Erasca in a report on Wednesday, October 8th. Finally, Piper Sandler assumed coverage on Erasca in a research report on Wednesday, January 7th. They set an &#34;overweight&#34; rating and a $5.00 target price on the stock. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, Erasca currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $5.44.</p>
<div class="lb-trans"><p>其他一些券商也对 ERAS 发布了报告。摩根士丹利在 1 月 8 日的研究报告中将 Erasca 的目标价设定为 4.00 美元。瑞穗证券在 12 月 9 日的研究报告中将 Erasca 的目标价从 4.00 美元上调至 5.00 美元，并给予该股票 “跑赢大盘” 的评级。Stifel Nicolaus 在周一的报告中将 Erasca 的目标价设定为 10.00 美元。Weiss Ratings 在 10 月 8 日的报告中重申了对 Erasca 的 “卖出（d-）” 评级。最后，Piper Sandler 在 1 月 7 日的研究报告中开始覆盖 Erasca，给予 “增持” 评级和 5.00 美元的目标价。七位分析师对该股票给予买入评级，一位给予持有评级，两位给予卖出评级。根据 MarketBeat 的数据，Erasca 目前的平均评级为 “适度买入”，平均目标价为 5.44 美元。</p>
</div><p><strong>Get Our Latest Stock Analysis on Erasca</strong></p>
<div class="lb-trans"><p><strong>获取我们对 Erasca 的最新股票分析</strong></p>
</div><h2>Insider Activity at Erasca</h2>
<div class="lb-trans"><h2>Erasca 的内部活动</h2>
</div><p>In other Erasca news, General Counsel Ebun Garner sold 120,000 shares of the business's stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $5.59, for a total value of $670,800.00. Following the transaction, the general counsel owned 25,076 shares of the company's stock, valued at approximately $140,174.84. The trade was a 82.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 14.40% of the company's stock.</p>
<div class="lb-trans"><p>在 Erasca 的其他新闻中，首席法律顾问 Ebun Garner 在 1 月 7 日的交易中出售了 120,000 股公司的股票。该股票以平均价格 5.59 美元出售，总价值为 670,800.00 美元。交易后，首席法律顾问持有 25,076 股公司的股票，价值约为 140,174.84 美元。此次交易使其持股减少了 82.72%。该交易已在提交给证券交易委员会的文件中披露，可以通过此超链接访问。公司内部人士持有公司股票的 14.40%。</p>
</div><h2>Institutional Investors Weigh In On Erasca</h2>
<div class="lb-trans"><h2>机构投资者对 Erasca 的看法</h2>
</div><p>A number of institutional investors and hedge funds have recently made changes to their positions in the stock. SG Americas Securities LLC grew its holdings in Erasca by 233.3% during the fourth quarter. SG Americas Securities LLC now owns 48,677 shares of the company's stock worth $181,000 after purchasing an additional 34,072 shares during the period. CIBC Bancorp USA Inc. acquired a new stake in Erasca during the third quarter worth approximately $40,000. Vivo Capital LLC increased its holdings in Erasca by 37.2% in the 3rd quarter. Vivo Capital LLC now owns 9,273,428 shares of the company's stock valued at $20,216,000 after buying an additional 2,516,672 shares during the period. Paradigm Biocapital Advisors LP boosted its stake in Erasca by 13.9% in the third quarter. Paradigm Biocapital Advisors LP now owns 13,560,017 shares of the company's stock valued at $29,561,000 after buying an additional 1,652,835 shares in the last quarter. Finally, Creative Planning grew its stake in shares of Erasca by 43.4% during the third quarter. Creative Planning now owns 350,314 shares of the company's stock worth $764,000 after buying an additional 105,982 shares during the last quarter. Institutional investors own 67.78% of the company's stock.</p>
<div class="lb-trans"><p>最近，一些机构投资者和对冲基金对该股票的持仓进行了调整。SG Americas Securities LLC 在第四季度将其在 Erasca 的持股增加了 233.3%。SG Americas Securities LLC 目前持有 48,677 股公司股票，价值 181,000 美元，此前在该期间购买了 34,072 股。CIBC Bancorp USA Inc.在第三季度获得了 Erasca 的新股份，价值约为 40,000 美元。Vivo Capital LLC 在第三季度将其在 Erasca 的持股增加了 37.2%。Vivo Capital LLC 目前持有 9,273,428 股公司股票，价值 20,216,000 美元，此前在该期间购买了 2,516,672 股。Paradigm Biocapital Advisors LP 在第三季度将其在 Erasca 的股份增加了 13.9%。Paradigm Biocapital Advisors LP 目前持有 13,560,017 股公司股票，价值 29,561,000 美元，此前在上个季度购买了 1,652,835 股。最后，Creative Planning 在第三季度将其在 Erasca 的股份增加了 43.4%。Creative Planning 目前持有 350,314 股公司股票，价值 764,000 美元，此前在上个季度购买了 105,982 股。机构投资者持有公司 67.78% 的股票。</p>
</div><h2>Erasca Price Performance</h2>
<div class="lb-trans"><h2>Erasca 的价格表现</h2>
</div><p>The stock has a market capitalization of $2.31 billion, a P/E ratio of -17.98 and a beta of 1.15. The firm has a 50-day simple moving average of $3.46 and a 200 day simple moving average of $2.38.</p>
<div class="lb-trans"><p>该股票的市值为 23.1 亿美元，市盈率为-17.98，贝塔值为 1.15。该公司有 50 日简单移动平均线为 3.46 美元，200 日简单移动平均线为 2.38 美元。</p>
</div><p>Erasca (NASDAQ:ERAS - Get Free Report) last issued its earnings results on Wednesday, November 12th. The company reported ($0.11) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.11). Sell-side analysts anticipate that Erasca, Inc. will post -0.73 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Erasca（纳斯达克代码：ERAS - 获取免费报告）最近在 11 月 12 日发布了其财报。公司报告每股收益为（0.11 美元），符合分析师的共识预期（0.11 美元）。卖方分析师预计 Erasca, Inc.在当前财年将发布每股收益-0.73 美元。</p>
</div><h2>Erasca Company Profile</h2>
<div class="lb-trans"><h2>Erasca 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Erasca, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of precision medicines for patients with cancer. The company focuses on small molecule therapeutics that target critical signaling pathways involved in tumor growth and survival, with a primary emphasis on inhibitors of the MAPK pathway. Erasca's approach is designed to deliver oral, targeted therapies that address both oncogene‐driven and immuno‐oncology indications, aiming to improve outcomes for patients with unmet medical needs.</p>
<div class="lb-trans"><p>Erasca, Inc 是一家临床阶段的生物制药公司，致力于为癌症患者发现和开发精准医疗。该公司专注于小分子治疗药物，针对肿瘤生长和存活中涉及的关键信号通路，主要强调 MAPK 通路的抑制剂。Erasca 的方案旨在提供口服的靶向治疗，解决肿瘤基因驱动和免疫肿瘤学的适应症，旨在改善满足医疗需求的患者的治疗效果。</p>
</div><p>Erasca's pipeline comprises multiple development candidates, including small molecule inhibitors engineered to disrupt key nodes in cancer cell signaling.</p>
<div class="lb-trans"><p>Erasca 的研发管线包括多个开发候选药物，包括旨在干扰癌细胞信号传导关键节点的小分子抑制剂。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Erasca</li>
<li>The Crash Has Already Started (Most Just Don’t See It Yet)</li>
<li>Trump Planning to Use Public Law 63-43: Prepare Now</li>
<li>“Ominous day” coming to stocks…</li>
<li>If You Keep Cash In A U.S. Bank Account… Read This NOW</li>
<li>Punch these codes into your ordinary brokerage account</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Erasca 更好</li>
<li>崩盘已经开始（大多数人只是不知道而已）</li>
<li>特朗普计划利用公共法 63-43：现在准备好</li>
<li>股票即将迎来 “不祥之日”……</li>
<li>如果你在美国银行账户中存放现金……请立即阅读</li>
<li>将这些代码输入你的普通经纪账户</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Erasca Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Erasca 吗？</h2>
</div><p>Before you consider Erasca, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Erasca 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Erasca wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每日推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐现在购买，以便在更广泛的市场意识到之前……而 Erasca 并不在名单上。</p>
</div><p>While Erasca currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Erasca 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Erasca（NASDAQ:ERAS）在分析师上调评级后股价上涨 7.7%